10-Q: Capricor Therapeutics Faces FDA Setback, Reports Wider Losses

Capricor Therapeutics received a Complete Response Letter from the FDA for its Deramiocel BLA, requiring additional clinical data, while reporting significantly increased net losses for the nine months ended September 30, 2025.

Summary

• Net loss for the three months ended September 30, 2025, was $24.6 million, compared to $12.6 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $74.9 million, compared to $33.4 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities totaled approximately $98.6 million as of September 30, 2025, a decrease from $151.5 million at December 31, 2024.
• The FDA issued a Complete Response Letter (CRL) for Deramiocel's Biologics License Application (BLA) in July 2025, citing insufficient evidence of effectiveness and outstanding Chemistry, Manufacturing, and Controls (CMC) items.
• The FDA agreed that the HOPE-3 Phase 3 trial should serve as the additional study requested in the CRL, and its data may be submitted within the existing BLA; topline data is expected in the fourth quarter of 2025.
• The Phase 1 clinical trial for the StealthX vaccine (exosome platform) initiated in August 2025, with initial data expected in the first quarter of 2026.
• The company has an accumulated deficit of approximately $274.7 million as of September 30, 2025.
• Management stated there is "substantial doubt" about the company's ability to continue as a going concern, as current funds are only sufficient into the fourth quarter of 2026.
• Research and development expenses increased by 72% to $20.4 million for the three months ended September 30, 2025, and by 73% to $61.3 million for the nine months ended September 30, 2025, primarily due to increased headcount, HOPE-3 trial costs, manufacturing efforts, and exosome platform research.
• General and administrative expenses increased by 71% to $5.9 million for the three months ended September 30, 2025, and by 67% to $17.7 million for the nine months ended September 30, 2025, driven by higher headcount, recruiting, professional services, and corporate overhead.
• No revenue was recognized for the three and nine months ended September 30, 2025, compared to $2.3 million and $11.1 million in the respective prior periods, as all $50.0 million in U.S. distribution agreement milestones have been recognized.
• Three legal proceedings, including a putative securities class action, a derivative action, and a shareholder demand letter, were initiated against the company and its management in July, August, and October 2025.

Sentiment

Score: 3

Explanation: The FDA's Complete Response Letter for Deramiocel's BLA is a major setback, delaying potential market approval and increasing financial pressure. The company reported substantially wider losses and issued a going concern warning, indicating significant liquidity challenges. While there are some positive clinical updates for Deramiocel and progress on the exosome platform, the immediate regulatory and financial outlook is concerning.

Positives

• The FDA agreed that the HOPE-3 Phase 3 trial data can be submitted within the existing BLA for Deramiocel, providing a clear path forward for resubmission.
• The FDA confirmed Performance of the Upper Limb (PUL v2.0) as the primary efficacy endpoint and left ventricular ejection fraction (LVEF) measured by cMRI as an appropriate key secondary endpoint for Deramiocel.
• Deramiocel continues to demonstrate a strong and consistent safety profile, with over 800 infusions administered to approximately 150 Duchenne muscular dystrophy (DMD) patients without significant safety signals.
• Positive four-year outcomes from the HOPE-2 Open-Label Extension (OLE) study showed sustained preservation of cardiac function and a slowing in skeletal muscle decline in DMD patients.
• Deramiocel has received multiple regulatory designations, including Orphan Drug Designation (U.S. FDA, European Medicines Agency), Regenerative Medicine Advanced Therapy (RMAT) designation (U.S.), Advanced Therapy Medicinal Product (ATMP) designation (Europe), and Rare Pediatric Disease Designation (FDA), which may qualify for a Priority Review Voucher.
• The Phase 1 clinical trial for the StealthX vaccine (exosome platform) initiated in August 2025, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) under Project NextGen, advancing the exosome technology.
• Investment income significantly increased to approximately $4.2 million for the nine months ended September 30, 2025, from $1.5 million in the prior year, due to a higher principal balance in marketable securities.

Negatives

• Received a Complete Response Letter (CRL) from the FDA for Deramiocel's BLA, indicating that the current application did not meet the statutory requirement for substantial evidence of effectiveness and requires additional clinical data.
• Reported a significant increase in net loss, reaching $24.6 million for the three months ended September 30, 2025 (up from $12.6 million in 2024) and $74.9 million for the nine months ended September 30, 2025 (up from $33.4 million in 2024).
• No revenue was recognized in the three or nine months ended September 30, 2025, a decrease from $2.3 million and $11.1 million in the respective prior periods.
• Cash, cash equivalents, and marketable securities decreased by approximately $52.9 million from December 31, 2024, to September 30, 2025.
• The company explicitly stated "substantial doubt about the Company's ability to continue as a going concern" as current funds are only sufficient into the fourth quarter of 2026.
• Research and development expenses increased by 73% for the nine months ended September 30, 2025, to $61.3 million, and general and administrative expenses increased by 67% to $17.7 million, contributing to wider losses.
• Three legal proceedings (securities class action, derivative action, shareholder demand letter) were initiated against the company and its management in July, August, and October 2025.
• Uncertainty exists regarding NIAID's resources to fund a Phase 2 study for the StealthX vaccine due to a government shutdown.

Risks

• Inability to obtain additional financing (equity, debt, licensing, grants) when needed or on favorable terms, which could lead to significant delays, curtailment, or termination of clinical trials and R&D programs.
• Substantial dilution for existing stockholders if additional equity securities are issued to raise capital.
• Debt financing, if available, may involve restrictive covenants that limit operational flexibility.
• Relinquishing some rights to technologies or product candidates or granting licenses on unfavorable terms if funds are raised through collaboration and licensing arrangements.
• Failure to complete the development of product candidates in a timely manner, which would materially adversely affect future revenue, results of operations, and financial position.
• Uncertainty in predicting the duration and cost of clinical trials due to unanticipated events, patient recruitment rates, manufacturing costs, and regulatory approvals.
• Costs and time associated with defending securities class action litigation, derivative claims, and shareholder demand letters, potentially diverting management attention and harming the business, leading to a decline in stock price.
• Uncertainty regarding NIAID's resources to fund a Phase 2 study for the StealthX vaccine due to a government shutdown.
• Accrued interest on the California Institute for Regenerative Medicine (CIRM) Award could reach up to approximately $7.9 million and continue to accrue over time until the final payout, depending on the terms of the loan agreement currently under discussion.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future, anticipating a substantial need for additional funding to support the development and commercialization of Deramiocel and its exosome programs. Current cash resources are projected to fund operations only into the fourth quarter of 2026. Topline data from the HOPE-3 Phase 3 clinical trial is expected in the fourth quarter of 2025, which the company plans to submit with a formal complete response to the BLA, aiming for a label encompassing cardiac and potentially skeletal muscle function. The BLA resubmission is expected to undergo a Type 2 review, with an anticipated approval timeline of up to six months. Discussions have been initiated with health authorities in Europe and Japan to define potential approval pathways for Deramiocel. Initial data from the Phase 1 StealthX vaccine study is expected in the first quarter of 2026, though uncertainty exists regarding NIAID funding for a potential Phase 2 study due to a government shutdown. The company plans to spend $50.0 million to $55.0 million on the Deramiocel program and $7.0 million to $9.0 million on the exosome program in 2025, and continues to explore potential partnerships.

Management Comments

• "We expect to incur significant expenses and operating losses for the foreseeable future."
• "Our ability to eventually generate any product revenue sufficient to achieve profitability will depend on the successful development, approval and eventual commercialization of Deramiocel for the treatment of DMD and our other product candidates."
• "If we fail to raise capital or other potential funding or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of Deramiocel or our other product candidates."
• "Developing biological products is a lengthy and very expensive process."
• "Our success depends not only on the safety and efficacy of our product candidates, but also on our ability to finance the development of our products and our clinical programs."
• "Based on our current cash resources and projected operating plan, we do not have sufficient funds to support operations for at least twelve months from the filing date of this Quarterly Report on Form 10-Q. Accordingly, substantial doubt exists about our ability to continue as a going concern."

Industry Context

The company operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on rare diseases like Duchenne muscular dystrophy (DMD) and advanced therapeutic platforms such as cell and exosome-based therapies. The receipt of a Complete Response Letter (CRL) from the FDA for a Biologics License Application (BLA) is a common, albeit significant, setback in drug development, underscoring the stringent regulatory environment and the high bar for demonstrating substantial evidence of effectiveness. The pursuit of exosome-based therapeutics and vaccines, including collaborations with government initiatives like Project NextGen and NIAID for SARS-CoV-2, aligns with broader industry trends in novel drug delivery and infectious disease preparedness. The substantial R&D expenditures and ongoing operating losses are typical for clinical-stage biotech companies that have not yet achieved commercialization, highlighting the inherent risks and long development timelines in this industry.

Comparison to Industry Standards

• The company's financial position, characterized by substantial operating losses and an explicit 'going concern' warning, is not uncommon for clinical-stage biotechnology firms heavily invested in research and development without commercial products, but it signals a heightened level of financial risk compared to more established, revenue-generating pharmaceutical companies.
• The FDA's Complete Response Letter (CRL) for Deramiocel, requiring additional clinical data, indicates that the initial BLA submission did not meet the 'substantial evidence of effectiveness' standard, which is a high regulatory hurdle. This outcome is a frequent challenge in the biotech industry, where regulatory approval is highly dependent on robust Phase 3 data, and it places Capricor in a position similar to other companies facing delays in their lead programs.
• The utilization of Orphan Drug, Regenerative Medicine Advanced Therapy (RMAT), Advanced Therapy Medicinal Product (ATMP), and Rare Pediatric Disease designations for Deramiocel aligns with standard industry strategies to accelerate development, gain market exclusivity, and potentially secure a Priority Review Voucher for rare disease treatments.
• The collaborations with Nippon Shinyaku for commercialization in the U.S., Japan, and potentially Europe, represent a common industry approach for smaller biotech companies to leverage larger partners' commercial infrastructure and mitigate market entry risks.
• The development of an exosome platform and participation in government initiatives like Project NextGen for vaccine development (e.g., against SARS-CoV-2) reflects a competitive landscape where companies seek to innovate in high-impact areas, often through partnerships to share development costs and expertise.

Corporate Governance

Legal Proceedings

• On July 17, 2025, a putative securities class action was filed in the Southern District of California, naming Capricor Therapeutics, Inc. and CEO Linda Marbn, alleging violations of U.S. federal securities laws and seeking unspecified damages.
• On August 1, 2025, a derivative action was filed in the Southern District of California naming each member of the Board of Directors of Capricor Therapeutics, Inc., alleging, among other things, breaches of fiduciary duties and seeking unspecified damages.
• On October 2, 2025, the company received a Section 220 Shareholder Demand Letter dated September 30, 2025, to inspect and make copies of certain books and records, related to alleged false and misleading statements by officers and directors and alleged failure to disclose material adverse facts.

Related Party Transactions

• Consulting Agreement with Dr. Frank Litvack, Executive Chairman and Board member, for $10,000 per month for consulting services.
• Consulting Agreement with Michael Kelliher, a Board member, in January 2024, granting an option to purchase 30,000 shares for business development services.
• Commercialization and Distribution Agreements with Nippon Shinyaku Co., Ltd. (a related party holding more than 10% of outstanding capital stock) for the U.S. and Japan territories.
• Binding Term Sheet with Nippon Shinyaku for the commercialization and distribution of Deramiocel in the European region.
• Private Placement of 2,798,507 shares of common stock to Nippon Shinyaku for approximately $15.0 million on September 16, 2024.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity financings, increased stock price volatility due to regulatory setbacks and financial uncertainty, and the impact of ongoing legal proceedings.
• Employees are affected by increased headcount in R&D and G&A, with stock-based compensation being a significant component of their remuneration, but also face uncertainty given the 'going concern' warning.
• Patients with Duchenne muscular dystrophy (DMD) may experience delays in accessing Deramiocel due to the FDA's Complete Response Letter, although continued progress in the HOPE-3 trial and positive HOPE-2 OLE data offer ongoing hope for future treatment options.
• Partners, particularly Nippon Shinyaku, are impacted by the regulatory delays for Deramiocel, which could affect their commercialization timelines and revenue expectations, despite ongoing collaboration for multiple markets.
• Creditors face increased risk due to the company's 'going concern' warning and the potential for significant accrued interest on the CIRM Award, which has been converted into a loan.

Next Steps

• Release topline data from the HOPE-3 Phase 3 clinical trial in the fourth quarter of 2025.
• Submit HOPE-3 results with a formal complete response to the BLA to the FDA.
• Seek FDA review of the BLA resubmission under a Type 2 classification (anticipated review up to six months).
• Initiate discussions with health authorities in Europe and Japan to define potential approval pathways for Deramiocel.
• Obtain initial data from the Phase 1 StealthX vaccine study in the first quarter of 2026.
• Negotiate with NIAID for potential funding of a Phase 2 StealthX study.
• Finalize a definitive commercialization and distribution agreement with Nippon Shinyaku for the European region by November 30, 2025.
• Address the "going concern" issue by seeking additional financing through equity or debt issuances, licensing or sale of technology, and potential government grants.
• Continue discussions with Shiraz Partners LP to extend the lease term for manufacturing facilities.
• Continue discussions with Entos Pharmaceuticals US, Inc. to extend the sublease term for office and research space.
• Continue discussions with Explora BioLabs, Inc. to extend the vivarium agreement.
• Finalize the terms of the CIRM Award conversion into a loan.
• Defend against the putative securities class action, derivative action, and shareholder demand letter.

Key Dates

Recommendation

The FDA's Complete Response Letter for Deramiocel's BLA is a critical setback, significantly delaying market entry for the company's lead product candidate and raising substantial regulatory uncertainty. This, coupled with a dramatic increase in net losses (over 100% year-over-year for the nine-month period) and an explicit "going concern" warning, indicates severe financial distress and operational challenges. The company's cash runway is limited to Q4 2026, necessitating further capital raises that will likely result in significant shareholder dilution. The initiation of multiple legal proceedings (securities class action, derivative action, shareholder demand) further compounds the negative outlook, suggesting potential governance issues and additional financial burdens. While there are some positive clinical data points and ongoing trials, the immediate regulatory and financial risks are overwhelming, making the stock a strong sell for investors.

Keywords

Duchenne muscular dystrophy, Deramiocel, Cell therapy, Exosomes, Biotechnology, Clinical trial, FDA BLA, Complete Response Letter, Going concern, CAPR, Rare disease, Cardiomyopathy, StealthX vaccine, SEC filing, Financial results